Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов)

1. Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач. 2009; 12: 39-42.
2. ESH-ESC Guidelines committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
3. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009; 27: 2121–58.
4. Диагностика и лечение метаболического синдрома. Российские рекомендации. Москва 2009 г. Кардиоваскул. тер. и профилак. 2009; 6 (Прил. 2).
5. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. Кардиоваскул. тер. и профилак. 2009; 6 (Прил. 3).
6. Devereux R, Reicheck N. Echocardiographic determinstion of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613–18.
7. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145–53.
8. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. On reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–88.
9. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. Чазова И.Е., Ратова Л.Г., исследователи «Клип-Аккорд». КЛИП-АККОРД: 4 года и 7796 пациентов – возможности полнодозовой комбинированной терапии артериальной гипертонии. Систем. гипертенз. 2008; 1: 4–9.
11. Чазова И.Е., Ратова Л.Г.. Комбинированная терапия у пациентов с артериальной гипертонией. Системные гипертензии 2010; 2: 6–10.
12. ONTARGET Investigators, Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
13. Veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028–34.
14. Psaty B, Smith N, Siscovick D et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45.
15. Psaty B, Lumley T, Furberg C. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003; 289: 2534–44.
16. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
17. Wiysonge C, Bradley H, Mayosi B, et al. Beta blockers for hypertension. Cochrane Database Rev 2007; 1: CD002003.
18. Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
19. Чазова И.Е., Мартынюк Т.В., Колос И.П. Первые результаты Российской программы СТРАТЕГИЯ у пациентов с артериальной гипертензией: оценка эффективности Нолипрела при недостаточном контроле артериального давления. Cons. med. 2007; 9(5): 5–10.
20. Чазова И.Е., Беленков Ю.Н., Ратова Л.Г. и др. От идеи к клинической практике. Первые результаты российского национального исследования оптимального снижения артериального давления (РОСА). Систем. гипертенз. 2004; 2: 18–23.
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
22. Ryden L, Standl E, Bartnik M et al. Task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC); European association for the study of diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88–136.
23. Beckett N, Peters R, Fletcher A et al; the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
24. Lithell H, Hansson L, Skoog I et al., SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
25. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
26. Fox K, Ferrari R, Yusuf S, Borer J. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function? Eur Heart J 2006; 27: 2154–57.
27. Martin J, Thigpen B, Moore R et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105: 246–54.
28. Podymow Т, August Ph. Update on the Use of Antihypertensive Drugs in Pregnancy. Hypertension 2008; 51: 960–69.
29. Grodski S, Jung C, Kertes P et al. Phaeochromocytoma in pregnancy. Intern Med J 2006; 36: 604–6.
30. Hanssens M, Keirse M, Vankelecom F, Van Assche F. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gyn 1991; 78: 128–35.
31. Briggs G, Freeman R, Yaffe S. Drugs in Pregnacy and lactation. Seventh Edition. A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams&Wilkins 2005.
32. Groves T, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gyn 1995; 172: 1655–56.
33. Asthma and COPD (Second Edition) Basic Mechanisms and Clinical Management. Ed. P.J. Barnes Academic Press, Elsevier Ltd. 2009; 584-85.
34. Dogra S, Ardern C, Baker J. The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma 2007; 44: 849–54.
35. Asthma. Ed by F. Chung. Eur Respir Mon. 2003; 8: 295.
36. Dart R, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003; 123: 222–43.
37. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 19: CD003566.
38. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308: 18–21.
39. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101–7.
40. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol 1985; 20 (Suppl. 2): S289–98.
41. The Global Strategy for Asthma Management and Prevention (updated 2009) www.ginasthma.org.
42. The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2009), the Executive Summary (updated 2009), www.goldcopd.org.
43. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137: 20–30.

И.Е.Чазова, председатель (Москва), Л.Г.Ратова, секретарь (Москва), С.А.Бойцов (Москва), Д.В.Небиеридзе (Москва)

________________________________________________

I.E.Chazova, Chairman (Moscow); L.G.Ratova, Secretary (Moscow); S.A.Boitsov (Moscow), D.V.Nebieridze (Moscow)